Times are shown in your local time zone GMT
Ad-blocker Detected - Your browser has an ad-blocker enabled, please disable it to ensure your attendance is not impacted, such as CPD tracking (if relevant). For technical help, contact Support.
Richard Lee
Vice Chair, ISPE Korea & Chief Executive Officer and Member of the Board - LOTTE BIOLOGICS
Professional Bio
Richard Lee is the Chief Executive Officer of LOTTE Biologics and has been serving on its Board of Directors since 2022.
After joining LOTTE as the Vice President of Corporate Development in 2021, Mr. Lee successfully led the acquisition deal of Bristol-Myers Squibb’s Syracuse Plant and completed the Post-Merger Integration of the US Plant with the Korean LOTTE Biologics group in the following year.
Prior to joining LOTTE Biologics, Mr. Lee was a founding member of Samsung Biologics and successfully led its Drug Product Business Unit providing strategic direction across finance, business development, HR, technical operations, regulatory management, expansion engineering, and supply chain management.
With vast industry experience across industry leaders such as Samsung Biologics, Quality Assurance at Bristol-Myers Squibb, and Technical Operation at Chiron, Mr. Lee has developed a strong, quality-driven approach to delivering biopharmaceuticals.
Mr. Lee holds a bachelor's degree from the University of California, Berkeley majoring in Molecular Biology.
After joining LOTTE as the Vice President of Corporate Development in 2021, Mr. Lee successfully led the acquisition deal of Bristol-Myers Squibb’s Syracuse Plant and completed the Post-Merger Integration of the US Plant with the Korean LOTTE Biologics group in the following year.
Prior to joining LOTTE Biologics, Mr. Lee was a founding member of Samsung Biologics and successfully led its Drug Product Business Unit providing strategic direction across finance, business development, HR, technical operations, regulatory management, expansion engineering, and supply chain management.
With vast industry experience across industry leaders such as Samsung Biologics, Quality Assurance at Bristol-Myers Squibb, and Technical Operation at Chiron, Mr. Lee has developed a strong, quality-driven approach to delivering biopharmaceuticals.
Mr. Lee holds a bachelor's degree from the University of California, Berkeley majoring in Molecular Biology.